Compass Pathways PLC Sponsored ADR $CMPS Shares Newly Acquired by Lisanti Capital Growth LLC

Lisanti Capital Growth LLC acquired a new position in Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) in the 3rd quarter, Holdings Channel reports. The institutional investor acquired 198,400 shares of the company’s stock, valued at approximately $2,468,000.

A number of other institutional investors have also recently bought and sold shares of the business. Orbimed Advisors LLC bought a new stake in Compass Pathways in the 1st quarter valued at about $6,363,000. Affinity Asset Advisors LLC grew its position in Compass Pathways by 454.2% during the first quarter. Affinity Asset Advisors LLC now owns 1,108,483 shares of the company’s stock worth $6,130,000 after buying an additional 908,483 shares in the last quarter. Eversept Partners LP acquired a new stake in Compass Pathways during the first quarter worth approximately $3,749,000. CenterBook Partners LP increased its stake in Compass Pathways by 454.1% during the 3rd quarter. CenterBook Partners LP now owns 695,943 shares of the company’s stock worth $8,658,000 after acquiring an additional 570,349 shares during the period. Finally, Eagle Health Investments LP increased its stake in Compass Pathways by 35.6% during the 1st quarter. Eagle Health Investments LP now owns 2,060,427 shares of the company’s stock worth $11,394,000 after acquiring an additional 541,039 shares during the period. Institutional investors own 46.19% of the company’s stock.

Key Headlines Impacting Compass Pathways

Here are a few of the latest headlines about CMPS:

• Positive Sentiment: HC Wainwright’s updated estimates project narrower losses: its FY2026 EPS forecast improved to ($1.40) from ($1.58), and its FY2027 forecast to ($1.17) from ($1.56). The firm also raised estimates across the reported quarters through 2027 and maintained its Buy rating. Better-than-previous forecasts may support investor sentiment, though the company is still expected to post losses. Compass Pathways analyst estimates
• Neutral Sentiment: Compass Pathways plans to attend the Jefferies Global Healthcare Conference on November 18–19, including a fireside chat and panel. The appearance could provide investor visibility, but the announcement did not disclose new company developments. Conference announcement

Compass Pathways Price Performance

Shares of NASDAQ:CMPS opened at $9.30 on Thursday. The firm has a 50 day moving average of $12.06 and a 200-day moving average of $10.44. Compass Pathways PLC Sponsored ADR has a 12 month low of $4.88 and a 12 month high of $15.87. The company has a current ratio of 1.50, a quick ratio of 1.50 and a debt-to-equity ratio of 0.35. The stock has a market capitalization of $1.32 billion, a PE ratio of -2.66 and a beta of 2.43.

Compass Pathways (NASDAQ:CMPS) last posted its quarterly earnings results on Tuesday, November 3rd. The company reported ($0.31) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.39) by $0.08. On average, equities research analysts predict that Compass Pathways PLC Sponsored ADR will post -0.78 EPS for the current fiscal year.

Wall Street Analyst Weigh In

CMPS has been the subject of several analyst reports. BTIG Research reaffirmed a “buy” rating and issued a $25.00 price objective on shares of Compass Pathways in a report on Tuesday, November 3rd. B. Riley Financial increased their target price on Compass Pathways from $17.00 to $22.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. Wells Fargo & Company reduced their target price on Compass Pathways from $13.00 to $10.00 and set an “equal weight” rating on the stock in a report on Wednesday, November 4th. Oppenheimer restated an “outperform” rating and issued a $20.00 price target on shares of Compass Pathways in a research report on Tuesday, November 3rd. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Compass Pathways in a research note on Thursday, October 15th. One research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $23.14.

Compass Pathways Company Profile

Compass Pathways plc is a biotechnology company developing treatments for mental health conditions. Founded in 2016 by George Goldsmith and Ekaterina Malievskaia, the company is focused on advancing psychedelic-based therapies through clinical research. Its lead investigational product, COMP360, is a synthetic formulation of psilocybin being studied alongside psychological support. Compass is evaluating COMP360 primarily as a potential treatment for treatment-resistant depression and has also explored its use for other mental health conditions, including post-traumatic stress disorder.